These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28930612)

  • 1. Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.
    Blum K; Chen ALC; Thanos PK; Febo M; Demetrovics Z; Dushaj K; Kovoor A; Baron D; Smith DE; Roy AK; Fried L; Chen TJH; Chapman E; Modestino EJ; Steinberg B; Badgaiyan RD
    Front Biosci (Elite Ed); 2018 Jan; 10(1):175-196. PubMed ID: 28930612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.
    Moran M; Blum K; Ponce JV; Lott L; Gondré-Lewis MC; Badgaiyan S; Brewer R; Downs BW; Fynman P; Weingarten A; Cadet JL; Smith DE; Baron D; Thanos PK; Modestino EJ; Badgaiyan RD; Elman I; Gold MS
    Mol Neurobiol; 2021 Jul; 58(7):3335-3346. PubMed ID: 33683627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Benefits of Genetic Addiction Risk Score (GARS
    Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
    Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility.
    Blum K; Hauser M; Fratantonio J; Badgaiyan RD
    Addict Genet; 2015 Jul; 2(1):1-5. PubMed ID: 26807291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors.
    Gupta A; Bowirrat A; Gomez LL; Baron D; Elman I; Giordano J; Jalali R; Badgaiyan RD; Modestino EJ; Gold MS; Braverman ER; Bajaj A; Blum K
    Int J Environ Res Public Health; 2022 Jan; 19(1):. PubMed ID: 35010811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions.
    Chen AL; Chen TJ; Waite RL; Reinking J; Tung HL; Rhoades P; Downs BW; Braverman E; Braverman D; Kerner M; Blum SH; DiNubile N; Smith D; Oscar-Berman M; Prihoda TJ; Floyd JB; O'Brien D; Liu HH; Blum K
    Med Hypotheses; 2009 Jan; 72(1):14-22. PubMed ID: 18951726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
    Blum K; Baron D; McLaughlin T; Gold MS
    J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics and prescription opioid use.
    Benjeddou M; Peiró AM
    Pharmacogenomics; 2021 Mar; 22(4):235-245. PubMed ID: 33445954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.
    Blum K; Badgaiyan RD; Agan G; Fratantonio J; Simpatico T; Febo M; Haberstick BC; Smolen A; Gold MS
    J Reward Defic Syndr; 2015; 1(1):65-68. PubMed ID: 26052557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine.
    Abijo T; Blum K; Gondré-Lewis MC
    Curr Neuropharmacol; 2020; 18(7):578-595. PubMed ID: 31744450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
    Gold MS; Baron D; Bowirrat A; Blum K
    J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.
    Kreek MJ; Levran O; Reed B; Schlussman SD; Zhou Y; Butelman ER
    J Clin Invest; 2012 Oct; 122(10):3387-93. PubMed ID: 23023708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
    Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
    Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
    Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
    CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential paradigm shift in opioid crisis management: The role of pharmacogenomics.
    Eapen-John D; Mohiuddin AG; Kennedy JL
    World J Biol Psychiatry; 2022 Jul; 23(6):411-423. PubMed ID: 34854362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression.
    Nikoshkov A; Drakenberg K; Wang X; Horvath MC; Keller E; Hurd YL
    Proc Natl Acad Sci U S A; 2008 Jan; 105(2):786-91. PubMed ID: 18184800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative addictive potential of opioid analgesic agents.
    Connors NJ; Mazer-Amirshahi M; Motov S; Kim HK
    Pain Manag; 2021 Mar; 11(2):201-215. PubMed ID: 33300384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
    Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
    J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
    Blum K; Modestino EJ; Neary J; Gondré-Lewis MC; Siwicki D; Moran M; Hauser M; Braverman ER; Baron D; Steinberg B; Laughlin TM; Badgaiyan RD
    Biomed J Sci Tech Res; 2018 Jan; 2(2):1-4. PubMed ID: 30370423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
    Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.